Novartis's Myfortic granted Australian orphan status
25 January 2010
Becky Debens
Please Login to read the full article.
25 January 2010
Becky Debens
Novartis's immunosuppressant Myfortic (mycophenolic acid sodium 180mg/360mg) has been granted orphan status by the Australian
Therapeutics Goods Administration (TGA) for the induction and maintenance treatment of lupus nephritis – which causes inflammation of the kidney. It received...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Iron chelator, prostate cancer conundrum on deck for ODAC
- US Capitol Capsule: FDA's CDER ends 2011 with 30 new drugs and biologics
- US FDA targets 17 April 2012 for Qnexa decision; Vivus shares rise
- Vivus narrows indication for Qnexa obesity drug to FDA to enable Q2 2012 approval
COMMENT
Other Informa Comment
FEATURES
Other Informa Features
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
